This variability is only partly accounted for by new additions in WHO 2021 such as the presence of CDKN2A/B homozygous deletion for IDH-mutant astrocytomas and additional molecular features of glioblastoma for IDH-wildtype gliomas [2]. Here, IDH2 is linked to central nervous system cancer.